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We report a 69-years-old Iranian HIV negative male patient, with long-standing pulmonary tuberculosis
(eleven years) co-infected with non-tuberculosis mycobacteria. Despite of initiation of ﬁrst line anti-
tuberculosis therapy after diagnosis the patient poorly respond because of low compliance with anti-
TB treatment. After several incomplete treatments the smear was still positive and thus drug suscepti-
bility tests were performed on isolated organism which revealed that the organisms was resistant not
only against isoniazid and rifampin but also against Oﬂoxacin (OFX), Capreomycin (CAP), p-amino-
salicylic acid (PAS), ethionamide (ETH), Kanamycin (KAN), ciproﬂoxacin (Cip), amikacin (AMK) and
cycloserine (CYC). Persistence and resistance of infection had led us to do more investigation using
molecular methods, which revealed co-infection with Non-tuberculosis mycobacteria (NTM). The patient
is still alive with cough and shortness of breath.
© 2015 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
There were an estimated 8.7e9 million new cases of tuber-
culosis annually and 1.4 million people died from TB during 2011.
The emergence of drugs resistant strains of Mycobacterium
tuberculosis has been considered a serious threat for global health
and control of tuberculosis. Extensively drug-resistant Mycobac-
terium tuberculosis (XDR-TB) is a rare form of drug-resistances
which is not susceptible against the second-line anti-tubercular
regimen in particular ﬂuoroquinolones and any of injectable
drugs (Amikacin, Kanamycin, or Capreomycin) in addition to the
ﬁrst-line anti-TB regimen (resistance to at least isoniazid and
rifampin) [1,2]. XDR-TB has been reported by 84 countries with
high rate of mortality [3]. XDR-TB raises concerns for restricted
treatment options [4]. Individuals with a history of lung damage
are susceptible to non-tuberculosis mycobacteria (NTM). Co-
existence of TB and NTM led to inaccurate diagnosis and inap-
propriate treatment [5].þ98 5138453239.
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A 69-years-old male patient was referred to physician with
complains of cough for 3 months, tiredness and weight loss during
September 2002 in north east of Iran. The patient indicated no
history of fever at night and chills and also no family history of
pulmonary tuberculosis. In examination no underlying disease and
HIV was detected but he was heavy smoker. Three sputum samples
were obtained over a 3-day period for acid-fast bacilli (AFB) smears
and culture. The direct smearswere positive for AFB, and his disease
was diagnosed as pulmonary tuberculosis. He received standard
anti-TB treatment recommended by WHO, consisting of rifampin
(RIF), isoniazid (INH), ethambutol (EMB) andpyrazinamide (PZA) for
two months, followed by four months of RIF and INH while his
compliancewas low. InMarch 2003, hisweight increased andmajor
health improvement was noticed. The smear was negative and
consequently the treatment was stopped. In April 2003, because of
symptoms recurrence, treatment was begun according to cat II as
follow: two months treatment with RIF, INH, EMB, PZA and strep-
tomycin (STR), followed by one month of RIF, INH, EMB and PZA,
followed by ﬁve months RIF, INH and EMB. In January 2004 patient
was admitted with hemoptysis. At this time direct smear wasC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. Chest radiography showing bilateral inﬁltration in upper lobes.
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was performed. The exams resulted in positive culture which was
resistance against RIF, INH, EMB and STR. The patient was hospi-
talized for 124 days in the National Research Institute of Tubercu-
losis and Lung Diseases (NRITLD) (Tehran, Iran) and treatment was
started with second-line anti-tubercular regimen consisting cipro-
ﬂoxacin (Cip), amikacin (AMK), prothionamide (PTH), cycloserine
(CYC), clarithromycin (CLR), amoxicillin-clavulanate and vitaminB6.
The patient poorly followed his treatment for several years in spite
of symptoms. In May 2008, because of no response to treatment,
drug sensitivity test was performed for second-line anti-tubercular
regimen using two critical proportions of 1% and 10%. The result
(after 42 days incubation at 37 C) showed resistance against Ami-
kacin, Ciproﬂoxacin, Cycloserine, Oﬂoxacin (OFX), Capreomycin
(CAP), p-aminosalicylic acid (PAS), ethionamide (ETH), Kanamycin
(KAN). In August 2012, due to unusual persistence and resistance of
infection, more investigationwas recommended using biochemical
molecular methods and therefore sputum culture and drug sensi-
tivity test was performed in Regional Tuberculosis Reference Labo-
ratory in Mashhad. It showed that direct smear and sputum culture
was still positive for AFB. In September 2012, direct smear and
culturewas repeatedly positive andduring this timedue todigestive
side effects, the patient refused to use regular drugs consumption.
Mycobacterium isolatedwasniacin negative andhad smooth colony
and was resistance against RIF, INH, EMB and STR. PCR was per-
formed on isolated mycobacterium that revealed NTM (unknown
species). Formore conﬁrmation, another sputumsamplewas sent to
NRITLD on January 2013. Using molecular methods particularly
Spoligotyping, the isolated strain was identiﬁed as M. tuberculosis.
In March 2013, chest radiography revealed a bilateral inﬁltration in
upper lobes (Fig. 1).
At that time his laboratory values were as follow: white blood
cell (70.6% neutrophils) and red blood cell count were normal,
Hemoglobin: 18.8 g/dL, Hematocrit: 58.5 mL/dL, urea: 47 mL/dL, Cr:
1.4 mL/dL, Aspartate aminotransferase (AST): 23 IU/L, Alanine
aminotransferase (ALT): 19 IU/L. On physical examination, his blood
pressure was 90/60 mmHg, his weight was 55 kg. The patient still
complained of cough and shortness of breath.
Discussion and conclusion
XDR-TB is a form of tuberculosis that are resistant to most of
anti-TB drugs. XDR-TB increases concerns of a tuberculosis due torestricted treatment options, and strongly jeopardizes the
achievements made by TB control. It is vital that this form of
tuberculosis co-infected with other bacteria, be accurately and
rapidly diagnosed. The main concerns and points regarding our
case are as follow: The direct smears always were positive except
for two times, after initiation of treatment with ﬁrst-line regimen at
ﬁrst diagnosis and, during treatment with second-line regimen in
combination with clarithromycin and amoxicillin-clavulanate. This
strain has probably become resistance against ﬁrst and second line
regimen due to poor compliance during these years. Co-existing
NTM with M. tuberculosis due to pre-existing lung disease could
interpret the symptoms and situation of the patient. Despite lack of
sign and symptom, smears remain positive because of NTM. It
should be considered that M. tuberculosis may be omitted even if
NTM is detected. It must be noticed that NTMs do not show suitable
response to anti-tuberculosis drugs. The inaccurate diagnosis of TB
co-infected with NTM is still remains a big problem.
Another hypothesis is that NTM infections can diminish pro-
gression of M. tuberculosis and thus this theory gives explanation
for survival of the patient. And the patient is still alive without any
important problems. Another interesting point about the patient
was lack of considerable weight loss (53e55 kg) during this period.
There are some reports that show XDR-TB cases have died or had
serious problems [6e8]. In spite of not usingmask protection by the
patient, other family members were not infected.
Another possibility in this case is the presence of a new species
with characteristics similar to both XDR-TB and NTM. The fre-
quency and clinical signiﬁcance of NTM isolated from patients
during treatment for pulmonary tuberculosis has not been
adequately studied ([6,8e10]). More research still needs to be done
for more clariﬁcations. Finally it should be remembered that in any
tuberculosis patients with poor response to treatment, co-infection
with other bacteria especially NTM should be examined.Acknowledgment
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